Grn (Progranulin) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The GRN[2] gene (Granulin Precursor) encodes progranulin[1] cause
tau-negative Frontotemporal Dementia[3] linked to
chromosome 17. Nature. 2006;442(7105]:916-919. PMID:16816112" title="[Baker M, et al. Mutations in progranulin[1] cause
tau-negative Frontotemporal Dementia[3] linked to
chromosome 17. Nature. 2006;442(7105]:916-919. PMID:16816112">[1] (PGRN, a secreted glycoprotein with pleiotropic functions in cell
growth, wound healing, inflammation, lysosomal biology, and neuronal survival. Heterozygous loss-of-function mutations in GRN[1] cause ubiquitin-positive
Frontotemporal Dementia[3] linked to chromosome 17q21. Nature. 2006;442(7105]:920-924. PMID:16415884" title="[Cruts M, et al. Null mutations in
progranulin[1] cause ubiquitin-positive Frontotemporal Dementia[3] linked to chromosome 17q21. Nature.
2006;442(7105]:920-924. PMID:16415884">[2] are a major genetic cause of [Frontotemporal Dementia[1]-mutation
dosage. Am J Hum Genet. 2012;90(6]:1102-1107. PMID:22842149" title="[Smith KR, et al. Strikingly different clinicopathological phenotypes determined by progranulin[1]-mutation
dosage. Am J Hum Genet. 2012;90(6]:1102-1107. PMID:22842149">[3]] (FTD), accounting for 5-10% of all FTD cases
and up to 20% of familial FTD. The disease mechanism is haploinsufficiency: a single functional GRN[2] allele produces approximately
50% of normal progranulin[1] levels, which is insufficient to maintain neuronal health (Baker et al., 2006;
Cruts et al., 2006).
Homozygous GRN[2] mutations cause an entirely different disease - neuronal ceroid lipofuscinosis type 11 (CLN11), a lysosomal storage
disorder - highlighting progranulin[1]'s essential role in lysosomal function (Smith et al., 2012). Progranulin has
also emerged as a protective factor in Alzheimer's disease, with genetic evidence supporting the therapeutic potential of raising progranulin[1] cause tau-negative Frontotemporal Dementia[3] linked to chromosome 17. Nature. 2006;442(7105]:916-919. PMID:16816112"
title="[Baker M, et al. Mutations in progranulin[1] cause
tau-negative Frontotemporal Dementia[3] linked to chromosome 17. Nature. 2006;442(7105]:916-919. PMID:16816112">[1] levels across
multiple neurodegenerative conditions.
¶ Gene Structure and Protein
- Chromosomal location: 17q21.31
- Gene structure: 13 exons spanning ~3.7 kb of coding sequence
- Transcript: Encodes a 593-amino acid precursor protein
- Expression: Broadly expressed; highest CNS expression in microglia
The GRN gene is located on chromosome 17q21.31 and consists of 13 exons spanning approximately 3.7 kb. The gene encodes a precursor protein (progranulin) that is cleaved by extracellular proteases into smaller, active granulin peptides.### Protein Structure
Progranulin is a 68.5 kDa secreted glycoprotein with a unique modular structure:
- Seven-and-a-half granulin domains (paragranulin + granulins A-G), each containing a conserved 12-cysteine motif
- Signal peptide (amino acids 1-17) directs secretion
- N-linked glycosylation sites (4 sites) important for stability and trafficking
- Protease cleavage sites between granulin domains: extracellular proteases (elastase, proteinase 3, MMP-12, MMP-14, ADAMTS-7) cleave progranulin[1] into individual granulin peptides
The full-length progranulin[1] and its cleaved granulin peptides can have opposing biological
activities: progranulin[1] is generally anti-inflammatory,
while individual granulins (particularly granulin E) can be pro-inflammatory.
Progranulin reaches the lysosome through two pathways:
- Sortilin-dependent: Progranulin binds the sorting receptor sortilin (SORT1), which mediates endocytosis and lysosomal delivery
- Prosaposin-dependent: Progranulin forms a complex with prosaposin for lysosomal targeting via the mannose-6-phosphate receptor and LRP1
Progranulin participates in:
- Cell proliferation and survival: Acts as a growth factor
- Wound healing: Promotes angiogenesis and tissue repair
- Inflammation regulation: Modulates immune responses
- Lysosomal function: Critical for neuronal maintenance
- ** synaptic function**: Involved in synaptic plasticity### Lysosomal Biology
Progranulin is essential for lysosomal homeostasis:
- Regulates lysosomal acidification and enzyme activity
- Modulates the activity of lysosomal hydrolases including cathepsins and glucocerebrosidase (GCase)
- Maintains lysosomal membrane integrity
- Required for proper autophagic flux
- Granulin E serves as a co-factor for lysosomal sphingolipid metabolism
Loss of progranulin[1] leads to lipofuscin accumulation, impaired autophagy, and lysosomal storage pathology - the basis of CLN11 disease (Paushter et al., 2018).
- Neurotrophic factor: Promotes neuronal survival and neurite outgrowth (Van Damme et al., 2008)
- Synaptic maintenance: Regulates synaptic density and plasticity
- Neuroprotection: Protects against excitotoxicity and oxidative stress
- Anti-inflammatory: Full-length progranulin[1] antagonizes TNF-alpha signaling by competing for TNF receptors
- Microglial homeostasis: Maintains microglial surveillance phenotype; loss causes microglial hyperactivation
- Complement regulation: Modulates complement cascade activation
- Cross-talk with TREM2: Progranulin interacts with the TREM2-DAP12 signaling pathway in [microglia
Over 70 pathogenic GRN[2] mutations have been identified in FTD patients:
| Mutation Type |
Frequency |
Mechanism |
| Frameshift |
~40% |
Premature termination; NMD of mRNA |
| Nonsense |
~25% |
Premature stop codon; NMD |
| Splice site |
~15% |
Aberrant splicing; exon skipping |
| Missense |
~10% |
Impaired secretion or stability |
| Genomic deletions |
~5% |
Loss of exons or entire gene |
| Regulatory |
~5% |
Reduced transcription |
NMD = nonsense-mediated mRNA decay. Most mutations lead to complete loss of the mutant allele's protein product.
The primary disease mechanism is haploinsufficiency - a 50% reduction in progranulin[1] levels is insufficient to sustain normal lysosomal and neuronal function:
- Heterozygous carriers have ~50% normal plasma progranulin[1] levels
- Complete progranulin[1] loss (homozygous mutations) causes CLN11, not FTD
- Gene dosage determines disease: one functional allele leads to FTD; zero functional alleles leads to NCL
- Reduced progranulin[1] leads to enhanced TDP-43 pathology, lysosomal dysfunction, and microglial hyperactivation
The primary disease mechanism is haploinsufficiency:
-
Heterozygous mutations reduce progranulin levels by ~50%
-
Complete loss is embryonic lethal in mice
-
Reduced progranulin leads to:
- Increased neuronal vulnerability
- Enhanced TDP-43 pathology
- Lysosomal dysfunction### Inheritance and Penetrance
-
Autosomal dominant inheritance with age-dependent penetrance
-
Penetrance: ~50% by age 60, ~90% by age 70, nearly complete by age 80
-
Variable expressivity: Even within families, clinical presentation varies substantially
-
Genetic modifiers include TMEM106B (risk variant rs1990622), which significantly modifies age of onset and disease risk
GRN[2]-FTD is characterized by TDP-43 type A pathology:
- TDP-43 mislocalization from nucleus to cytoplasm
- Neuronal cytoplasmic inclusions (NCIs)
- Neuronal intranuclear inclusions (NIIs) - relatively specific to GRN[2]-FTD
- Short dystrophic neurites (DNs)
- TDP-43 pathology severity correlates with progranulin[1] deficiency
Progranulin deficiency causes progressive lysosomal failure:
- Lipofuscin-like storage material accumulation (resembling NCL pathology)
- Impaired glucocerebrosidase activity leading to ceramide and glucosylceramide accumulation
- Defective autophagic flux leading to accumulation of autophagic substrates
- Lysosomal membrane permeabilization releasing cathepsins into the cytoplasm
- Secondary ferroptosis from impaired lipid metabolism
GRN[2]-FTD is accompanied by intense neuroinflammation:
- Microglial hyperactivation with disease-associated microglia (DAM phenotype)
- Elevated complement C1q and C3 leading to excessive synaptic pruning
- Increased pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta)
- Astrocytic reactivity (GFAP elevation)
- Cross-talk with TREM2 signaling pathways
GRN[2]-related FTD presents with several clinical syndromes:
- Behavioral variant FTD (bvFTD): 60-70% of cases; early personality change, disinhibition, apathy, loss of empathy
- Primary progressive aphasia (PPA): 20-30% of cases, typically nonfluent/agrammatic variant; progressive language impairment
- Corticobasal syndrome (CBS): 5-10%; asymmetric parkinsonism, limb apraxia, alien limb phenomenon
- Alzheimer's disease phenocopy: Rare; amnestic presentation mimicking AD
Compared to other genetic FTD causes (C9orf72, MAPT):
- Asymmetric atrophy: Often markedly lateralized cortical atrophy on MRI
- Parietal involvement: More parietal cortex involvement than MAPT-FTD
- Later onset: Mean onset age 58-65 (vs. 45-55 for MAPT-associated FTD)
- Shorter duration: Mean disease duration 6-8 years
- White matter changes: Prominent white matter hyperintensities on MRI
- Structural MRI: Asymmetric frontal, temporal, and parietal atrophy; prominent white matter changes
- FDG-PET: Asymmetric frontotemporal and parietal hypometabolism
- amyloid PET: Typically negative (differentiates from AD)
- Tau PET: Shows non-AD tau] patterns in some cases
Plasma progranulin[1] is the most reliable biomarker for GRN[2] mutation carrier status:
- GRN[2] mutation carriers: ~50% of normal levels (< 70 ng/mL typically)
- Homozygous carriers: Undetectable levels
- Normal range: 150-250 ng/mL
- Used for screening and therapeutic monitoring (Finch et al., 2009)
- **Neurofilament light chain **: Elevated in symptomatic carriers; predicts onset 1-2 years before symptoms
- Progranulin: Reduced in CSF; may better reflect CNS progranulin[1] levels than plasma
- Asymmetric cortical atrophy rate on serial MRI
- FDG-PET hypometabolism progression
- Presymptomatic carriers show subtle white matter changes before symptom onset
Multiple AAV-based gene therapy programs are in clinical development:
- PR006 (Prevail/Lilly): AAV9-GRN[2] delivered via intracisternal injection. The PROCLAIM Phase 1/2 trial showed safety and CSF progranulin[1] increases in the low-dose cohort at 12 months, with a mid-dose cohort (n=7) also enrolling (Bhalla et al., 2024)
- PBFT02 (Passage Bio): AAV1-GRN[2] delivered intracisternally; Phase 1/2 ongoing
- AVB-101 (Avrobio): AAV9-GRN[2] delivered via intrathalamic injection
Sortilin mediates progranulin[1] endocytosis and lysosomal degradation. Blocking sortilin raises circulating progranulin[1] levels:
- Latozinemab (AL001, Alector/AbbVie): Anti-sortilin monoclonal antibody. Received FDA Breakthrough Therapy Designation in February 2024 for FTD-GRN[2]. However, the Phase 3 INFRONT-3 trial did not demonstrate statistically significant slowing of disease progression, raising questions about the therapeutic window and whether progranulin[1] elevation alone is sufficient in symptomatic patients.
- Sortilin inhibitors (oral): VES001 (Vesper Bio) is an oral small-molecule sortilin inhibitor. Phase 1b/2a results (SORT-IN-2 study) in asymptomatic GRN[2] carriers showed CSF progranulin[1] levels nearly doubled over 3 months, reaching near-normal levels - a promising result for presymptomatic intervention.
- [HDAC] inhibitors: Increase GRN[2] transcription via epigenetic mechanisms
- Suberoylanilide hydroxamic acid (SAHA): Increases progranulin[1] mRNA expression in vitro
- SSRIs and trazodone for behavioral symptoms
- Speech and language therapy for PPA
- Occupational therapy and caregiver support
- No approved disease-modifying therapies as of 2025
Recent genetic evidence supports a protective role for progranulin[1] in Alzheimer's disease:
- Common GRN[2] variants that increase progranulin[1] levels are associated with reduced AD risk
- Progranulin modulates microglial amyloid-beta clearance via TREM2 interactions
- Higher plasma progranulin[1] levels correlate with slower cognitive decline in AD cohorts
- Therapeutic progranulin[1] elevation is being explored as a potential AD therapy (Bellenguez et al., 2022)
Homozygous GRN[2] loss-of-function mutations cause CLN11, distinct from FTD:
- Onset: Young adulthood (20-30 years)
- Symptoms: Progressive vision loss, myoclonic seizures, cerebellar ataxia, cognitive decline
- Pathology: Widespread lipofuscin accumulation confirming lysosomal storage
- Diagnosis: Undetectable plasma progranulin[1] + skin biopsy showing lipofuscin
- Prognosis: Progressive neurological deterioration
- Demonstrates that progranulin[1] is essential for lysosomal function in a dose-dependent manner
¶ Genetics and Epidemiology
- Carrier frequency: ~1 in 300-500 in European populations
- Geographic clusters: Higher frequency in Belgium, Italy (Brescia), and Canada (British Columbia) due to founder effects
- Lower frequency in East Asian and African populations
- TMEM106B rs1990622 is the most significant genetic modifier of disease risk and age of onset
- Null mutations (frameshift, nonsense): Earlier onset, more predictable presentation
- Missense mutations: Variable effect; some reduce secretion, others impair stability
- Splice site mutations: Variable severity depending on effect on protein expression
- No clear correlation between specific mutation and clinical syndrome
- [Microglia](/cell-types/microglia ### Phenotypic Presentation)
GRN-related FTD typically presents as:
- Behavioral variant FTD (bvFTD): 60-70% of cases
- Primary progressive aphasia (PPA): 20-30% of cases
- Corticobasal syndrome: Rare presentation
- Early behavioral disinhibition
- Apathy and loss of empathy
- Language impairment (aphasia)
- Memory relatively preserved early
- Parkinsonism in some cases
- Mean disease duration: 6-12 years
- More rapid progression than sporadic FTD
- Often progresses to severe dementia
- Progranulin: Reduced in CSF of mutation carriers
- Neurofilament light chain (NfL): Elevated
- Total tau: Moderately elevated
- Gene therapy: AAV-delivered GRN expression
- Protein replacement: Recombinant progranulin
- Small molecules: Upregulate residual GRN expression
- ASOs targeting GRN mRNA to reduce toxic transcripts
- Currently in preclinical development
- SSRIs for behavioral symptoms
- Occupational and speech therapy
- Supportive care
- Progranulin biology and function
- TDP-43 pathology mechanisms
- Lysosomal dysfunction in neurodegeneration
- Biomarker development
- No approved disease-modifying therapies yet
- Multiple trials in development
- Focus on progranulin restoration
The GRN gene (Granulin) encodes progranulin, a secreted glycoprotein that plays crucial roles in cell growth, wound healing, inflammation, and neuronal survival. Mutations in GRN are a major genetic cause of Frontotemporal Dementia (FTD), accounting for approximately 5-10% of all FTD cases and up to 20% of familial FTD cases.
The study of Grn (Progranulin) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Baker M, et al. Mutations in progranulin[1] cause tau-negative Frontotemporal Dementia[3] linked to chromosome 17. Nature. 2006;442(7105]:916-919. PMID: 16816112
- [Cruts M, et al. Null mutations in progranulin[1] cause ubiquitin-positive Frontotemporal Dementia[3] linked to chromosome 17q21. Nature. 2006;442(7105]:920-924. PMID: 16415884
- [Smith KR, et al. Strikingly different clinicopathological phenotypes determined by progranulin[1]-mutation dosage. Am J Hum Genet. 2012;90(6]:1102-1107. PMID: 22842149
- [Paushter DH, et al. The lysosomal function of progranulin[1], a guardian against neurodegeneration. Acta Neuropathol. 2018;136(1]:1-17. DOI
- [Bhalla A, et al. Progranulin AAV gene therapy for Frontotemporal Dementia[3]: translational studies and phase 1/2 trial interim results. Nat Med. 2024;30(5]:1489-1497. DOI
- [Gass J, et al. Mutations in progranulin[1] are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006;15(20]:2988-3001. DOI
- [Finch N, et al. Plasma progranulin[1] levels predict progranulin[1] mutation status in Frontotemporal Dementia[3] patients and asymptomatic family members. Brain. 2009;132(3]:583-591. DOI
- [Mackenzie IR, et al. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin[1] gene. Brain. 2006;129(11]:3081-3090. DOI
- [Bellenguez C, et al. New insights into the genetic etiology of Alzheimer's Disease and related dementias. Nat Genet. 2022;54(4]:412-436. DOI
- [Van Damme P, et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol. 2008;181(1]:37-41. DOI
- [Kao AW, et al. Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci. 2017;18(6]:325-333. DOI
- [Galimberti D, et al. Progranulin as a therapeutic target for dementia. Expert Opin Ther Targets. 2018;22(7]:579-585. DOI
- [Petkau TL, Bhalla A. GRN[2]-associated Frontotemporal Dementia[3]: therapeutic strategies and clinical trials. Mol Ther. 2024;32(10]:3178-3195. DOI